JAZZ

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases with significant unmet medical needs, particularly in neuroscience and oncology. The company is best known for Xyrem and Xywav, treatments for narcolepsy and idiopathic hypersomnia, which generate substantial revenue. Jazz markets Epidiolex for seizures associated with rare forms of epilepsy and Zepzelca for small cell lung cancer. The company maintains a robust pipeline of late-stage development programs and pursues strategic acquisitions to expand its portfolio.